Positron emission tomography imaging of brain tumors.

[1]  E. Malveaux,et al.  Radiolabeled amino acids for tumor imaging with PET: radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid. , 2002, Journal of medicinal chemistry.

[2]  Hui Wang,et al.  Radiolabeled 2′-fluorodeoxyuracil-β-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-β-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice , 2002, Cancer Chemotherapy and Pharmacology.

[3]  Jae Jeong,et al.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  R. Coleman,et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  H. Yamauchi,et al.  Quantitative Comparison of the Bolus and Steady-State Methods for Measurement of Cerebral Perfusion and Oxygen Metabolism: Positron Emission Tomography Study Using 15O-Gas and Water , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  G. Barnett,et al.  The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.

[7]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Shields,et al.  Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. , 2000, Nuclear medicine and biology.

[9]  Norbert Avril,et al.  Relevance of Positron Emission Tomography (PET) in Oncology , 1999, Strahlentherapie und Onkologie.

[10]  K. Leenders,et al.  Positron Emission Tomography in Patients with Primary CNS Lymphomas , 1999, Journal of Neuro-Oncology.

[11]  T. Turkington,et al.  Gangliogliomas: characterization by registered positron emission tomography-MR images. , 1999, AJR. American journal of roentgenology.

[12]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[13]  M. Sasaki,et al.  A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours , 1998, European Journal of Nuclear Medicine.

[14]  R. McLendon,et al.  Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. El-Saden,et al.  Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT. , 1998, AJNR. American journal of neuroradiology.

[16]  C. Degueldre,et al.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. P. Maguire,et al.  Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  K. Leenders,et al.  Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study , 1998, Journal of Neuro-Oncology.

[19]  N. Shinoura,et al.  PET imaging of brain tumor with [methyl-11C]choline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Hoffman,et al.  Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET) , 1996, International journal of STD & AIDS.

[21]  M. Maisey,et al.  FDG‐PET screening for cerebral metastases in patients with suspected malignancy , 1996, Nuclear medicine communications.

[22]  A. Dwyer,et al.  Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. , 1995, Journal of neurosurgery.

[23]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[24]  T. Turkington,et al.  Accuracy of Surface Fit Registration for PET and MR Brain Images Using Full and Incomplete Brain Surfaces , 1995, Journal of computer assisted tomography.

[25]  F. Shishido,et al.  Perfusion and metabolism in predicting the survival of patients with cerebral gliomas , 1994, Cancer.

[26]  Y Yonekura,et al.  PET and the autoradiographic method with continuous inhalation of oxygen-15-gas: theoretical analysis and comparison with conventional steady-state methods. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  T. Turkington,et al.  Accuracy of registration of PET, SPECT and MR images of a brain phantom. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  R. Coleman,et al.  Serial FDG‐PET Studies in the Prediction of Survival in Patients with Primary Brain Tumors , 1993, Journal of computer assisted tomography.

[29]  R. Coleman,et al.  FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  R. Coleman,et al.  FDG-PET in the selection of brain lesions for biopsy. , 1991, Journal of computer assisted tomography.

[31]  A. Friedman,et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.

[32]  J M Hoffman,et al.  Clinical application of PET for the evaluation of brain tumors. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  W. Paulus,et al.  Intratumoral histologic heterogeneity of gliomas. A quantitative study , 1989, Cancer.

[34]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[35]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[36]  C. Kufta,et al.  Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. , 1987, AJR. American journal of roentgenology.

[37]  G. di Chiro,et al.  Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. , 1987, Radiology.

[38]  G. Chiro.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[39]  M. Bergström,et al.  Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. , 1985, Journal of computer assisted tomography.

[40]  G Di Chiro,et al.  Prediction of survival in glioma patients by means of positron emission tomography. , 1985, Journal of neurosurgery.

[41]  M. Mintun,et al.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  R. Brooks,et al.  Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. , 1983, AJNR. American journal of neuroradiology.

[43]  K. Isselbacher.  Sugar and amino acid transport by cells in culture--differences between normal and malignant cells. , 1972, The New England journal of medicine.

[44]  M. Bergström,et al.  The normal pituitary examined with positron emission tomography and (methyl-11C)-L-methionine and (methyl-11C)-D-methionine , 2004, Neuroradiology.

[45]  R. Coleman,et al.  Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. , 2003, Radiology.

[46]  S. Goldman,et al.  Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. , 1997, Acta neurochirurgica. Supplement.

[47]  Susan M. Chang,et al.  18‐fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma , 1997, Cancer.

[48]  P. Conti.  Introduction to imaging brain tumor metabolism with positron emission tomography (PET). , 1995, Cancer investigation.

[49]  S. Goldman,et al.  PET in stereotactic conditions increases the diagnostic yield of brain biopsy. , 1994, Stereotactic and functional neurosurgery.

[50]  G. di Chiro,et al.  Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. , 1989, Neurosurgery.

[51]  E. Hoffman,et al.  A positron-emission transaxial tomograph for nuclear imaging (PETT). , 1975, Radiology.

[52]  R. Johnstone,et al.  Amino acid transport in tumor cells. , 1965, Advances in cancer research.